进行性表型慢性纤维化间质性肺疾病的诊断与预后生物标志物
本文综述了慢性纤维化间质性肺疾病(ILD)进行性表型中血清、BALF及遗传生物标志物的研究现状,按推测的病理生物学机制分类:上皮细胞功能障碍(如KL-6)、成纤维细胞增殖与细胞外基质产生或转换(如MMP-1)或免疫失调(如CCL18)。多数数据来自特发性肺纤维化(IPF),但更广泛的慢性纤维化ILD患者人群也有数据。一些生物标志物显示出前景,但均未经验证。本文评估了这些标志物在预测疾病风险或易感性、诊断、预后和治疗反应方面的地位,并直接比较IPF与其他慢性纤维化ILD,同时反思其当前临床实用性和未来研究方向。
要点
- KL-6、MMP-1、CCL18等生物标志物按病理机制分类,多数数据来自IPF。
- 这些生物标志物在风险预测、诊断、预后和治疗反应方面显示前景但均未经验证。
- 需直接比较IPF与其他慢性纤维化ILD中生物标志物的表现。
核心结论
- 一些生物标志物在慢性纤维化ILD进行性表型中显示前景,但均未经验证。
研究设计与样本
- 综述文章,总结血清、BALF和遗传生物标志物在慢性纤维化ILD进行性表型中的研究现状。
主要发现
- 生物标志物按推测机制分类:上皮细胞功能障碍(如KL-6)、成纤维细胞增殖与细胞外基质产生或转换(如MMP-1)、免疫失调(如CCL18)。
- 多数可用数据来自IPF,但更广泛的慢性纤维化ILD患者人群也有数据。
临床怎么用
- 评估生物标志物在预测疾病风险或易感性、诊断、预后和治疗反应方面的当前临床实用性。
局限性
- 所综述的生物标志物均未经验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Biomarkers have the potential to become central to the clinical evaluation and monitoring of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Here we summarize the current understanding of putative serum, BAL fluid, and genetic biomarkers in this setting, according to their hypothesized pathobiologic mechanisms: evidence of epithelial cell dysfunction (eg, Krebs von den Lungen-6 antigen), fibroblast proliferation and extracellular matrix production or turnover (eg, matrix metalloproteinase-1), or immune dysregulation (eg, CC chemokine ligand 18). While most of the available data come from idiopathic pulmonary fibrosis (IPF), the prototypic progressive fibrosing ILD, data are available in the broader patient population of chronic fibrosing ILDs. A number of these biomarkers show promise, however, none have been validated. In this review article, we assess both the status of proposed biomarkers for chronic fibrosing lung diseases with a progressive phenotype in predicting disease risk or predisposition, diagnosis, prognosis, and treatment response and provide a direct comparison between IPF and other chronic fibrotic ILDs. We also reflect on the current clinical usefulness and future direction of research for biomarkers in the setting of chronic fibrosing ILDs with a progressive phenotype.
引用
- Inoue Y, Kaner RJ, Guiot J, et al. Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest. 2020. PMID: 32268131. doi:10.1016/j.chest.2020.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。